MENUNeuroendocrine Tumor Clinical Trials
At the University of Michigan Rogel Cancer Center, our Prostate Cancer Program has a number of studies underway that are only available to our patients. We have extensive experience in selecting the right trial for each person.
Below is a list of some of the open trials. If you see one you may be eligible for or have questions, please call 800-865-1125 (Monday-Friday, 8am-5pm EST).
An Exploratory Study of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients with Neuroendocrine Tumor (Early Phase I)
Primary Investigator: Raffel, David
Purpose: The goal of this exploratory study is to test whether [18F]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of [18F]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Phase II trial of Pembrolizumab and Lenvatinib in Advanced/metastatic Neuroendocrine Prostate Cancer [PLANE-PC] (II)
Primary Investigator: Vaishampayan, Ulka
Purpose: Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
S2104, Randomized Phase II Trial of Postoperative adjuvant Capecitabine and Temozolomide versus observation in high-risk pancreatic neuroendocrine tumors
Primary Investigator: Sahai, Vaibhav
Purpose: This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
S2012, Randomized Phase II/III trial of first line platinum/etoposide with or without Atezolizumab (NSC#783608) in patients with poorly differentiated extrapulmonary small ell neuroendocrine carcinomas (NEC) (II/III)
Primary Investigator: Sahai, Vaibhav
Purpose: This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.